{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:46:05Z","timestamp":1750401965228,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11748-018-01058-3","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T12:08:24Z","timestamp":1548331704000},"page":"537-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II\/IIIA non-small cell lung cancer"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-1478","authenticated-orcid":false,"given":"Tomoshi","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"1058_CR1","doi-asserted-by":"publisher","first-page":"E359-86","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.","journal-title":"Int J Cancer"},{"key":"1058_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706\u201314.","journal-title":"J Thorac Oncol"},{"key":"1058_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura KFM. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs"},{"key":"1058_CR4","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M, Shi Y. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004\u201309.","journal-title":"Cancer Res"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1054\/bjoc.2001.2031","volume":"85","author":"M Kawahara","year":"2001","unstructured":"Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939\u201343.","journal-title":"Br J Cancer"},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.1158\/1078-0432.CCR-04-1200","volume":"10","author":"Y Ichinose","year":"2004","unstructured":"Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004;10:7860\u20134.","journal-title":"Clin Cancer Res"},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bjc.6605152","volume":"101","author":"F Ohyanagi","year":"2009","unstructured":"Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer. 2009;101:225\u201331.","journal-title":"Br J Cancer"},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2014.11.001","volume":"87","author":"N Nogami","year":"2015","unstructured":"Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, et al. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer. 2015;87:141\u201347.","journal-title":"Lung Cancer"},{"key":"1058_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrc.2016.02.010","volume":"7","author":"T Tsuchiya","year":"2016","unstructured":"Tsuchiya T, Nakamura Y, Hayashi N, Matsumoto K, Miyazaki T, Nakatomi K, et al. A multicenter phase II study of concurrent chemoradiotherapy with cisplatin and oral S-1, followed by surgery for locally advanced non-small-cell lung cancer. Cancer Treat Commun. 2016;7:11\u20136.","journal-title":"Cancer Treat Commun"},{"key":"1058_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"E Eisenhauer","year":"2009","unstructured":"Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","volume":"374","author":"KS Albain","year":"2009","unstructured":"Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379\u201386.","journal-title":"Lancet"},{"key":"1058_CR12","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.24492","volume":"115","author":"HB Caglar","year":"2009","unstructured":"Caglar HB, Baldini EH, Othus M, Rabin MS. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer. 2009;115:4156\u201366.","journal-title":"Cancer"},{"key":"1058_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.amsu.2017.03.025","volume":"17","author":"N Taira","year":"2017","unstructured":"Taira N, Kawasaki H, Furugen T, Ichi T, Kushi K, Yohena T, et al. The long-term prognosis of induction chemotherapy followed by surgery for N2 non-small cell lung cancer: a retrospective case series study. Ann Med Surg. 2017;17:65\u20139.","journal-title":"Ann Med Surg"},{"key":"1058_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.lungcan.2018.06.021","volume":"122","author":"LA Robinson","year":"2018","unstructured":"Robinson LA, Tanvetyanon T, Grubbs D, Antonia S, Creelan B, Fontaine J, et al. Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer. Lung Cancer. 2018;122:206\u201313.","journal-title":"Lung Cancer"},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.1990.8.5.911","volume":"8","author":"EE Vokes","year":"1990","unstructured":"Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990;8:911\u201334.","journal-title":"J Clin Oncol"},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/srao.2003.50002","volume":"13","author":"TS Lawrence","year":"2003","unstructured":"Lawrence TS, Blackstock W, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13:13\u201321.","journal-title":"Semin Radiat Oncol"},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0360-3016(98)00134-5","volume":"41","author":"JD Naida","year":"1998","unstructured":"Naida JD, Davis MA, Lawrence TS. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys. 1998;41:675\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.radonc.2010.05.020","volume":"96","author":"M Takagi","year":"2010","unstructured":"Takagi M, Sakata KI, Someya M, Tauchi H, Iijima K, Matsumoto Y, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010;96:259\u201366.","journal-title":"Radiother Oncol"},{"key":"1058_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00685830","volume":"32","author":"GN Schwartz","year":"1993","unstructured":"Schwartz GN, Teicher B, Eder JP, Korbut T, Holden S, Ara G, et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacot. 1993;32:167\u201372.","journal-title":"Cancer Chemother Pharmacot"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1073\/pnas.83.23.8923","volume":"83","author":"KJ Scanlon","year":"1986","unstructured":"Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA. 1986;83:8923\u201325.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1058_CR21","first-page":"2985","volume":"30","author":"N Yamamoto","year":"2010","unstructured":"Yamamoto N, Yamanaka T, Ichinose Y, Kubota K, Sakai H, Gemma A, et al. Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. Anticancer Res. 2010;30:2985\u201390.","journal-title":"Anticancer Res"},{"key":"1058_CR22","first-page":"2286","volume":"8","author":"RV Lord","year":"2002","unstructured":"Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286\u201391.","journal-title":"Clin Cancer Res"},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000438942","volume":"61","author":"T Tsuchiya","year":"2016","unstructured":"Tsuchiya T, Arai J, Matsumoto K, Miyazaki T, Honda S, Tagawa T, et al. Prognostic Impact of the ABCC11\/MRP8 polymorphism in adjuvant oral chemotherapy with S-1 for non-small cell lung cancer. Chemotherapy. 2016;61:77\u201386.","journal-title":"Chemotherapy"},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fonc.2018.00030","volume":"8","author":"B Jeremi\u0107","year":"2018","unstructured":"Jeremi\u0107 B, Casas F, Dubinsky P, Gomez-Caamano A, \u010cihori\u0107 N, Videtic G, et al. Treatment-related predictive and prognostic factors in trimodality approach in stage IIIA\/N2 non-small cell lung cancer. Front Oncol. 2018;8:30. \n                    https:\/\/doi.org\/10.3389\/fonc.2018.00030\n                    \n                  \n                           (eCollection).","journal-title":"Front Oncol"},{"key":"1058_CR25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.ejcts.2009.05.025","volume":"36","author":"ECJ Phernambucq","year":"2009","unstructured":"Phernambucq ECJ, Spoelstra FOB, Paul M, Senan S, Melissant CF, Postmus PE, et al. Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009;36:1052\u201357.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1058_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.5761\/atcs.oa.11.01811","volume":"18","author":"Y Shintani","year":"2012","unstructured":"Shintani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Maeda H, et al. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2012;18:530\u201335.","journal-title":"Ann Thorac Cardiovasc Surg"}],"container-title":["General Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-018-01058-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11748-018-01058-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-018-01058-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:22:01Z","timestamp":1579720921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11748-018-01058-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s11748-018-01058-3","relation":{},"ISSN":["1863-6705","1863-6713"],"issn-type":[{"type":"print","value":"1863-6705"},{"type":"electronic","value":"1863-6713"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have nothing to disclosure with regard to commercial support. The authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}